2. Academic Validation
  3. A disintegrin and metalloproteinase 22 activates integrin β1 through its disintegrin domain to promote the progression of pituitary adenoma

A disintegrin and metalloproteinase 22 activates integrin β1 through its disintegrin domain to promote the progression of pituitary adenoma

  • Neuro Oncol. 2024 Jan 5;26(1):137-152. doi: 10.1093/neuonc/noad148.
Biao Xing 1,  Zhuowei Lei 2,  Zihan Wang 1,  Quanji Wang 1,  Qian Jiang 1,  Zhuo Zhang 1,  Xiaojin Liu 1,  Yiwei Qi 1,  Sihan Li 1,  Xiang Guo 1,  Yanchao Liu 1,  Xingbo Li 1,  Kai Shu 1,  Huaqiu Zhang 1,  Jörg Walter Bartsch 3 4,  Christopher Nimsky 3 4,  Yimin Huang 1,  Ting Lei 1
Affiliations

Affiliations

  • 1 Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital of Tongji medical college of Huazhong University of Science and Technology, Wuhan, China.
  • 2 Department of Orthopedics, Tongji Hospital of Tongji medical college of Huazhong University of Science and Technology, Wuhan, China.
  • 3 Department of Neurosurgery, Philipps-University Marburg, University Hospital Marburg (UKGM), Marburg, Germany.
  • 4 Center for Mind, Brain and Behavior (CMBB), Marburg, Germany.
PMID: 37555799 DOI: 10.1093/neuonc/noad148
Abstract

Background: Approximately 35% of pituitary adenoma (PA) display an aggressive profile, resulting in low surgical total resection rates, high recurrence rates, and worse prognosis. However, the molecular mechanism of PA invasion remains poorly understood. Although "a disintegrin and metalloproteinases" (ADAMs) are associated with the progression of many tumors, there are no reports on ADAM22 in PA.

Methods: PA transcriptomics databases and clinical specimens were used to analyze the expression of ADAM22. PA cell lines overexpressing wild-type ADAM22, the point mutation ADAM22, the mutated ADAM22 without disintegrin domain, and knocking down ADAM22 were generated. Cell proliferation/invasion assays, flow cytometry, immunohistochemistry, immunofluorescence, co-immunoprecipitation, mass spectrometry, Reverse transcription-quantitative Real-Time PCR, phos-tag SDS-PAGE, and Western blot were performed for function and mechanism research. Nude mice xenograft models and rat prolactinoma orthotopic models were used to validate in vitro findings.

Results: ADAM22 was significantly overexpressed in PA and could promote the proliferation, migration, and invasion of PA cells. ADAM22 interacted with Integrin β1 (ITGB1) and activated FAK/PI3K and FAK/ERK signaling pathways through its disintegrin domain to promote PA progression. ADAM22 was phosphorylated by PKA and recruited 14-3-3, thereby delaying its degradation. ITGB1-targeted inhibitor (anti-itgb1) exerted antitumor effects and synergistic effects in combination with somatostatin analogs or dopamine agonists in treating PA.

Conclusions: ADAM22 was upregulated in PA and was able to promote PA proliferation, migration, and invasion by activating ITGB1 signaling. PKA may regulate the degradation of ADAM22 through post-transcriptional modification levels. ITGB1 may be a potential therapeutic target for PA.

Keywords

ADAM22; integrin β1; invasion | PKA; pituitary adenoma.

Figures
Products
Inhibitors & Agonists
Other Products